Literature DB >> 7533000

The shortest isoform of human vascular endothelial growth factor/vascular permeability factor (VEGF/VPF121) produced by Saccharomyces cerevisiae promotes both angiogenesis and vascular permeability.

S Kondo1, T Matsumoto, Y Yokoyama, I Ohmori, H Suzuki.   

Abstract

Vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) is a multifunctional cytokine that is expressed as four isoforms having 206, 189, 165, and 121 amino acids in humans. We constructed a system that produces the shortest isoform of human VEGF/VPF in Saccharomyces cerevisiae (yVEGF/VPF121). Active yVEGF/VPF121 was secreted from the yeast cells as a glycosylated dimeric protein. Various biological activities of the purified yVEGF/VPF121 were examined. It bound to cell surface receptor(s) and stimulated the growth of human umbilical vein endothelial cells in culture at a dose similar to that of native VEGF/VPF. Purified yVEGF/VPF121 also induced angiogenesis in mice, and promoted the extravasation of plasma proteins from the blood vessels. These observations demonstrated that the shortest isoform of VEGF/VPF with an amino acid sequence of 121 residues contains enough information necessary to trigger both angiogenesis and the induction of vascular permeability upon binding to its cognate receptor(s).

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7533000     DOI: 10.1016/0304-4165(94)00150-v

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  8 in total

Review 1.  A systems approach to cancer therapy. (Antioncogenics + standard cytotoxics-->mechanism(s) of interaction).

Authors:  B A Teicher
Journal:  Cancer Metastasis Rev       Date:  1996-06       Impact factor: 9.264

Review 2.  Tumor angiogenesis: the pivotal role of vascular endothelial growth factor.

Authors:  D Marmé
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

Review 3.  Similarities and differences between the vascular endothelial growth factor (VEGF) splice variants.

Authors:  G Neufeld; T Cohen; H Gitay-Goren; Z Poltorak; S Tessler; R Sharon; S Gengrinovitch; B Z Levi
Journal:  Cancer Metastasis Rev       Date:  1996-06       Impact factor: 9.264

4.  Expression and Characterization of Human Vascular Endothelial Growth Factor Produced in SiHa Cells Transduced with Adenoviral Vector.

Authors:  N C Parra; R Mansilla; G Aedo; N S Vispo; E E González-Horta; I González-Chavarría; C Castillo; F Camacho; O Sánchez
Journal:  Protein J       Date:  2019-12       Impact factor: 2.371

Review 5.  Neuropilin 1 Regulation of Vascular Permeability Signaling.

Authors:  Alison Domingues; Alessandro Fantin
Journal:  Biomolecules       Date:  2021-04-29

6.  Wide spectrum of antitumor activity of a neutralizing monoclonal antibody to human vascular endothelial growth factor.

Authors:  M Asano; A Yukita; H Suzuki
Journal:  Jpn J Cancer Res       Date:  1999-01

Review 7.  How VEGF-A and its splice variants affect breast cancer development - clinical implications.

Authors:  Hivin Al Kawas; Inas Saaid; Paul Jank; Christina C Westhoff; Carsten Denkert; Therese Pross; Karoline Barbara Stephanie Weiler; Maria Margarete Karsten
Journal:  Cell Oncol (Dordr)       Date:  2022-03-18       Impact factor: 7.051

Review 8.  Molecular diversity of VEGF-A as a regulator of its biological activity.

Authors:  Jeanette Woolard; Heather S Bevan; Steven J Harper; David O Bates
Journal:  Microcirculation       Date:  2009-06-01       Impact factor: 2.628

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.